Low-Molecular-Weight Heparins in the Treatment of Cancer-Associated Thrombosis: A New Standard of Care?

Seminars in Oncology

Volumn 33, Issue SUPPL. 4, 2006, Pages 3-16

  Burris III, Howard A ^a  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; BLOOD CLOTTING FACTOR; CLOPIDOGREL; CYCLOPHOSPHAMIDE; DALTEPARIN; ENOXAPARIN; EPIRUBICIN; ERYTHROPOIETIN; FIBRINOLYTIC FACTOR; FLUOROURACIL; FONDAPARINUX; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MITOMYCIN C; NADROPARIN; PLATINUM DERIVATIVE; TAMOXIFEN; THALIDOMIDE; THROMBIN; TICLOPIDINE; TINZAPARIN; TISSUE FACTOR PATHWAY INHIBITOR; VINCRISTINE; WARFARIN;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BLEEDING; CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CARDIOVASCULAR RISK; CELL INTERACTION; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DRUG MEGADOSE; HEPARIN ASSOCIATED THROMBOCYTOPENIA; HIGH RISK PATIENT; HUMAN; IMMUNOMODULATION; LONG TERM CARE; NEUTROPENIA; OSTEOPENIA; PATHOGENESIS; PRIORITY JOURNAL; THROMBOCYTE; THROMBOCYTOPENIA; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; NEOPLASMS; RISK FACTORS; SURGICAL PROCEDURES, OPERATIVE; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 33646032382     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2006.01.019     Document Type: Article

References (94)

1. American Cancer Society. Cancer Facts and Figures 2005 (2005), American Cancer Society, Atlanta, GA
2. Donati M.B. Cancer and thrombosis. Haemostasis 24 (1994) 128-131
3. Rickles F.R., and Levine M.N. Epidemiology of thrombosis in cancer. Acta Haematol 106 (2001) 6-12
4. Heit J.A., Silverstein M.D., Mohr D.N., et al. Risk factors for deep vein thrombosis and pulmonary embolism. A population-based case-control study. Arch Intern Med 160 (2000) 809-815
5. Lee A.Y.Y., and Levine M.N. Venous thromboembolism and cancer. Risks and outcomes. Circulation 107 (2003) 17-21 (suppl I)
6. Goodnough L.T., Saito H., Manni A., et al. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. A study of 159 patients. Cancer 54 (1984) 1264-1268
7. Blom J.W., Doggen C.J.M., Osanto S., et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293 (2005) 715-722
8. Levitan N., Dowlati A., Remick S.C., et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine 78 (1999) 285-291
9. Falanga A., Marchetti M., Giovanelli S., et al. All-trans-retinoic acid counteracts endothelial cell procoagulant activity induced by a human promyelocytic leukemia-derived cell line (NB4). Blood 87 (1996) 613-617
10. Colucci M., Balconi G., Lorenzet R., et al. Cultured human endothelial cells generate tissue factor in response to endotoxin. J Clin Invest 71 (1983) 1893-1896
11. Fareed J., Iqbal O., Tobu M., et al. Increased blood levels of inflammatory cytokines CRP, TNF-α, CD40L, MCP-1 and nitric oxide in malignancy-associated thrombosis and their modulation by a low molecular weight heparin, enoxaparin. J Clin Oncol 22 14S (2004) 538s (abstr 6077)
12. Bick R.L. Cancer-associated thrombosis. N Engl J Med 349 (2003) 109-111
13. Morgan M.A., Iyengar T.D., Napiorkowski B.E., et al. The clinical course of deep vein thrombosis in patients with gynecologic cancer. Gynecol Oncol 84 (2002) 67-71
14. Otten H.M., Mathijssen J., ten Cate H., et al. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy. An underestimated phenomenon. Arch Intern Med 164 (2004) 190-194
15. Priest J.R., Ramsay N.K., Steinherz P.G., et al. A syndrome of thrombosis and hemorrhage complicating L-asparaginase therapy for childhood acute lymphoblastic leukemia. J Pediatr 100 (1982) 984-989
16. Gugliotta L., Mazzucconi M.G., Leone G., et al., The GIMEMA Group. Incidence of thrombotic complications in adult patients with acute lymphoblastic leukaemia receiving L-asparaginase during induction therapy. A retrospective study. Eur J Haematol 49 (1992) 63-66
17. Zangari M., Anaissie E., Barlogie B., et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 98 (2001) 1614-1615
18. Barosi G., Elliott M., Canepa L., et al. Thalidomide in myelofibrosis with myeloid metaplasia. A pooled-analysis of individual patient data from five studies. Leuk Lymphoma 43 (2002) 2301-2307
19. Little R.F., Wyvill K.M., Pluda J.M., et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol 18 (2000) 2593-2602
20. Stebbing J., Benson C., Eisen T., et al. The treatment of advanced renal cell cancer with high dose oral thalidomide. Br J Cancer 85 (2001) 953-958
21. Figg W., Dahut W., Duray P., et al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 7 (2001) 1888-1893
22. Wang J., Weiss I., Svobada K., et al. Thrombogenic role of cells undergoing apoptosis. Br J Haematol 115 (2001) 382-391
23. Kaushal V., Kohli M., Zangari M., et al. Endothelial dysfunction antiangiogenesis-associated thrombosis. J Clin Oncol 20 (2002) 3042-3043
24. Desai A.A., Vogelzang N.J., Rini B.I., et al. A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer 95 (2002) 1629-1636
25. Zangari M., Siegel E., Barlogie B., et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide. Implications for therapy. Blood 100 (2002) 1168-1171
26. Weber D., Rankin K., Gavino M., et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21 (2003) 16-19
27. Zangari M., Barlogie B., Anaissie E., et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy. Effects of prophylactic and therapeutic anticoagulation. Br J Haematol 126 (2004) 715-721
28. Jacobson G.M., Kamath R.S., Smith B.J., et al. Thromboembolic events in patients treated with definitive chemotherapy and radiation therapy for invasive cervical cancer. Gynecol Oncol 96 (2005) 470-474
29. Falanga A. Thrombophilia in cancer. Semin Thromb Hemost 31 (2005) 104-110
30. Fernandez P.M., and Rickles F.R. Tissue factor and angiogenesis in cancer. Curr Opin Hematol 9 (2002) 401-406
31. Rickles F.R., Patierno S., and Fernandez P.M. Tissue factor, thrombin, and cancer. Chest 124 (2003) 58-68 (suppl)
32. Broze Jr. G.J. Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med 46 (1995) 103-112
33. Sandset P.M. Tissue factor pathway inhibitor (TFPI)-an update. Haemostasis 26 (1996) 154-165 (suppl 4)
34. Erman M., Abali H., Oran B., et al. Tamoxifen-induced tissue factor pathway inhibitor reduction. A clue for an acquired thrombophilic state?. Ann Oncol 15 (2004) 1622-1626
35. Hammerschmidt D.E. The newer LMW heparins. Effects on the tissue-factor pathway. J Lab Clin Med 144 (2004) 226-227
36. Brodin E., Svensson B., Paulssen R.H., et al. Intravascular release and urinary excretion of tissue factor pathway inhibitor during heparin treatment. J Lab Clin Med 144 (2004) 246-253
37. Hoppensteadt D.A., Jeske W., Fareed J., et al. The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin. Blood Coagul Fibrinolysis 6 (1995) 57-64 (suppl 1)
38. Hansen J.B., and Sandset P.M. Differential effects of low molecular weight heparin and unfractionated heparin on circulating levels of antithrombin and tissue factor pathway inhibitor (TFPI). A possible mechanism for difference in therapeutic efficacy. Thromb Res 91 (1998) 177-181
39. Goldenberg N., Kahn S.R., and Solymoss S. Markers of coagulation and angiogenesis in cancer-associated venous thromboembolism. J Clin Oncol 21 (2003) 4194-4199
40. Fareed D., Bick R., Baker P., et al. Nitric oxide levels are up-regulated in patients with malignancy associated hypercoagulable state. J Thromb Haemost 1 suppl 1 (2003) abstr P0847
41. Malyszko J., Malyszko J.S., Hryszko T., et al. Thrombin activatable fibrinolysis inhibitor (TAFI) and markers of endothelial cell injury in dialyzed patients with diabetic nephropathy. Thromb Haemost 91 (2004) 480-486
42. Malyszko J., Malyszko J.S., Hryszko T., et al. Comparison of effects of different heparins on thrombin activatable fibrinolysis inhibitor in hemodialyzed patients. Am J Nephrol 24 (2004) 624-629
43. Geerts W.H., Pineo G.F., Heit J.A., et al. Prevention of venous thromboembolism. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 338-400 (suppl 3)
44. Hyers T., Agnelli G., Russell H., et al. Antithrombotic therapy for venous thromboembolic diseases. Chest 119 (2002) 176-193 (suppl 1)
45. Buller H.R., Agnelli G., Hull R.D., et al. Antithrombotic therapy for venous thromboembolism. the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 401-428 (suppl 3)
46. Warkentin T.E., Greinacher A., and The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Heparin-induced thrombocytopenia. Recognition, treatment, and prevention. Chest 126 (2004) 311-337 (suppl 3)
47. Weitz J.I. Low-molecular-weight heparins. N Engl J Med 337 (1997) 688-698
48. Fragmin (dalteparin sodium) Prescribing Information (2004), Pfizer, New York, NY
49. Lovenox (enoxaparin sodium) Prescribing Information (2004), Aventis Pharmaceuticals Products Inc, Bridgewater, NJ
50. Innohep (tinzaparin sodium) Prescribing Information (2001), Pharmion, Boulder, CO
51. Hirsch J., Warkentin T.E., Shaughnessy S.G., et al. Heparin and low-molecular-weight heparin. Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 119 (2001) 64-94 (suppl)
52. Bick R.L., Frenkel E.P., Walenga J., et al. Unfractionated heparin, low molecular weight heparins, and pentasaccharide. Basic mechanisms of actions, pharmacology, and clinical use. Hematol Oncol Clin North Am 19 (2005) 1-51
53. Racine E. Differentiation of the low-molecular-weight heparins. Pharmacotherapy 21 (2001) 62-70 (suppl)
54. Levine M.N. Managing thromboembolic disease in the cancer patient. Efficacy and safety of antithrombotic treatment options in patients with cancer. Cancer Treat Rev 28 (2002) 145-149
55. Lee A.Y. Treatment of venous thromboembolism in cancer patients. Thromb Res 102 (2001) 195-208 (suppl V)
56. Douketis J., Foster G., Crowther M., et al. Clinical risk factors and timing of recurrent venous thromboembolism during the initial three months of therapy. Arch Intern Med 160 (2000) 3431-3436
57. Coumadin (warfarin sodium) Prescribing Information (2002), Bristol-Myers Squibb Company, Princeton, NJ
58. Palareti G., Legnani C., Lee A., et al. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost 84 (2000) 805-810
59. Zacharski L.R., Prandoni P., and Monreal M. Warfarin versus low-molecular-weight heparin therapy in cancer patients. The Oncologist 10 (2005) 72-79
60. Pini M., Aiello S., Manotti C., et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost 72 (1994) 191-197
61. Das S.K., Cohen A.T., Edmonson R.A., et al. Low-molecular weight heparin versus warfarin for prevention of recurrent venous thromboembolism. A randomized trial. World J Surg 20 (1996) 521-527
62. Lopaciuk S., Bielska-Falda H., Noszczyk W., et al. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thromb Haemost 81 (1999) 26-31
63. Gonzalez-Fajardo J., Arreba W., Castrodeza J., et al. Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep vein thrombosis. J Vasc Surg 30 (1999) 283-292
64. Veiga F., Escriba A., Maluenda M., et al. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep vein thrombosis in the elderly. A randomized trial. Thromb Haemost 84 (2000) 559-564
65. Lopez-Beret P., Orgaz A., Fontcuberta J., et al. Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis. J Vasc Surg 33 (2001) 77-90
66. Fareed J., Leong W.L., Hoppensteadt D.A., et al. Generic low-molecular-weight heparins. Some practical considerations. Semin Thromb Hemost 30 (2004) 703-713
67. Wells P.S., Anderson D.R., Rodger M.A., et al. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism. Arch Intern Med 165 (2005) 733-738
68. Kakkar A.K., Levine M., Pinedo H.M., et al. Venous thrombosis in cancer patients. Insights from the FRONTLINE survey. Oncologist 8 (2003) 381-388
69. Wolff R.A. Are patients with cancer receiving adequate thromboprophylaxis? Results from FRONTLINE. Cancer Treat Rev 29 (2003) 7-9 (suppl 2)
70. Wong J.E. Are patients with cancer receiving adequate treatment for thrombosis? Results from FRONTLINE. Cancer Treat Rev 29 (2003) 11-13 (suppl 2)
71. Deitcher S.R. Primary prevention of venous thromboembolic events (VTE) in cancer patients. An American survey study. J Clin Oncol 22 14S (2004) 750s (abstr 8086)
72. Lee A.Y., Levine M.N., Baker R.I., et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349 (2003) 146-153
73. ENOXACAN Study Group, and ENOXACAN Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery. A double-blind randomized multicentre trial with venographic assessment. Br J Surg 84 (1997) 1099-1103
74. McLeod R.S., Geerts W.H., Sniderman K.W., et al. Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery: Results of the Canadian colorectal DVT prophylaxis trial: A randomized, double-blind trial. Ann Surg 233 (2001) 438-444
75. Cohen A., Davidson B., Gallus A., et al. Fondaparinux for the prevention of VTE in acutely ill medical patients. Blood 102 (2003) 15 (abstr 42)
76. Agnelli G., Bergqvist D., Cohen A., et al. A randomized double-blind study to compare the efficacy and safety of fondaparinux with dalteparin in the prevention of venous thromboembolism after high-risk abdominal surgery. The Pegasus study. J Thromb Haemost 1 (2003) (suppl 1) (abstr OC006)
77. Bergqvist D., Agnelli G., Cohen A.T., et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 346 (2002) 975-980
78. Levine M., Hirsh J., Gent M., et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 343 (1994) 886-889
79. Lensing A.W., Prins M.H., Davidson B.L., et al. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch Intern Med 155 (1995) 601-607
80. Prandoni P., Lensing A.W., Piccioli A., et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100 (2002) 3484-3488
81. Meyer G., Marjanovic Z., Valcke J., et al. Comparison of low-molecular-weight heparin and warfarin for secondary prevention of venous thromboembolism in patients with cancer. A randomized controlled study. Arch Intern Med 162 (2002) 1729-1735
82. Monreal M., Zacharski L., Jimenez A., et al. Fixed-dose low-molecular-weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer. A prospective cohort study. J Thromb Haemost 2 (2004) 1311-1315
83. Hull R., Pineo G.F., Mah A.F., et al. A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months vs. intravenous heparin followed by warfarin sodium in patients with current cancer. J Thromb Haemost 1 suppl 1 (2003) abstr P1373a
84. Deitcher S.R., Kessler C.M., Merli G., et al. Secondary prevention of venous thromboembolic events (VTE) in patients with active malignancy. A randomized study of enoxaparin sodium alone versus initial enoxaparin sodium followed by warfarin for a 180-day period. Proc Soc Am Clin Oncol 22 (2003) 761 (abstr 3060)
85. Spyropoulos A.C., Frost F.J., Hurley J.S., et al. Costs and clinical outcomes associated with low-molecular-weight heparin vs unfractionated heparin for perioperative bridging in patients receiving long-term oral anticoagulant therapy. Chest 125 (2004) 1642-1650
86. Iorio A., Guercini F., Conti S., et al. Low molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism. meta-analysis of the randomized comparisons with oral anti-coagulants. J Thromb Haemost 1 suppl 1 (2003) abstr P1873
87. Lee A.Y.Y., Rickles F.R., Julian J.A., et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 23 (2005) 2123-2129
88. Kakkar A.K., Levine M.N., Kadziola Z., et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer. The Fragmin Advanced Malignancy outcome Study (FAMOUS). J Clin Oncol 10 (2004) 1944-1948
89. Klerk C.P.W., Smorenburg S.M., Otten H.-M., et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 10 (2005) 2130-2135
90. Altinbas M., Coskun H.S., Er O., et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2 (2004) 1266-1271
91. Robert F., Busby E., Marques M.B., et al. Phase II study of docetaxel plus enoxaparin in chemotherapy-naïve patients with metastatic non-small cell lung cancer. Preliminary results. Lung Cancer 42 (2003) 237-245
92. Elting L.S., Escalante C.P., Cooksley C., et al. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med 164 (2004) 1653-1661
93. Avritscher E.B., Cantor S.B., Shih Y.C., et al. Cost-minimization analysis of low-molecular-weight heparin (dalteparin) compared to unfractionated heparin for inpatient treatment of cancer patients with deep venous thrombosis. Support Care Cancer 12 (2004) 531-536
94. Nicolaides A.N., Breddin H.K., Fareed J., et al. Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance with the scientific evidence. Int Angiol 20 (2001) 1-37